Investigational drug · Phase 3
JS105
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumors, Breast Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Dec 30, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "JS105"
First trial start
2024
Jan 11, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JS105", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors
- Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "JS105" as an intervention, largest first.
Risen (Suzhou) Pharma Tech Co., Ltd.Industry
NCT07207070 · 312 participants (planned) · Start Nov 12, 2025 · Primary completion May 31, 2029
Drug: JS105; Dalpiciclib and 1 more · For: Breast Cancer
Sites: Beijing, China; Zhengzhou, China
Risen (Suzhou) Pharma Tech Co., Ltd.Industry
NCT06208410 · 306 participants (planned) · Start Jan 11, 2024 · Primary completion Feb 26, 2027
Drug: JS105; Fulvestrant injection and 6 more · For: Advanced Solid Tumors
Sites: Zhengzhou, China
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903Completed
Risen (Suzhou) Pharma Tech Co., Ltd.Industry
NCT06846099 · 69 participants · Start Dec 7, 2022 · Primary completion May 30, 2025
Drug: RP903 · For: Ovarian Cancer; Cervical Cancer; Endometrial Cancer and 2 more
Sites: Beijing, China; Bengbu, China; Changchun, China · 23 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Molecular epidemiology of clinical and carrier strains of methicillin resistant Staphylococcus aureus (MRSA) in the hospital settings of north India.
Dar JA, Thoker MA, Khan JA, et al. · Ann Clin Microbiol Antimicrob 2006
Also in development for Advanced Solid Tumors
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.